| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An EQ-5D-5L Value Set for Belgium
|
Bouckaert, Nicolas
|
|
|
6 |
6 |
p. 823-836
|
artikel
|
| 2 |
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
|
Cranmer, Holly
|
|
|
6 |
6 |
p. 881-892
|
artikel
|
| 3 |
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
|
Elsea, David
|
|
|
6 |
6 |
p. 899
|
artikel
|
| 4 |
Correction to: Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis
|
Allen, Keith B.
|
|
|
6 |
6 |
p. 897
|
artikel
|
| 5 |
Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification
|
Fabbro, Matthew
|
|
|
6 |
6 |
p. 773-786
|
artikel
|
| 6 |
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
|
Baharnoori, Moogeh
|
|
|
6 |
6 |
p. 859-870
|
artikel
|
| 7 |
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
|
Elsea, David
|
|
|
6 |
6 |
p. 811-822
|
artikel
|
| 8 |
Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
|
Gil, Fabio
|
|
|
6 |
6 |
p. 837-846
|
artikel
|
| 9 |
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
|
Blauvelt, Andrew
|
|
|
6 |
6 |
p. 871-880
|
artikel
|
| 10 |
Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis
|
Allen, Keith B.
|
|
|
6 |
6 |
p. 799-809
|
artikel
|
| 11 |
Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates
|
Breslau, Rachel Milstein
|
|
|
6 |
6 |
p. 893-895
|
artikel
|
| 12 |
The Cost of Flexible Bronchoscopes: A Systematic Review and Meta-analysis
|
Andersen, Carina Østervig
|
|
|
6 |
6 |
p. 787-797
|
artikel
|
| 13 |
What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care
|
Dale, Megan
|
|
|
6 |
6 |
p. 847-857
|
artikel
|
Tijdschrift beschrijving